• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The successful use of eculizumab for treatment of thrombotic microangiopathy in pediatric acute SARSCoV2 infection and multisystem inflammatory syndrome in children.

作者信息

Aurora Tarun, Joseph Noel, Bhoopalan Senthil Velan, Caniza Miguela A, Flerlage Tim, Ghafoor Saad, Hankins Jane, Hijano Diego R, Jesudas Rohith, Kirkham Justin, Martinez Hugo, Alfaro Gabriela Maron, Sharma Akshay, Hines Melissa

机构信息

Department of Clinical Education, St Jude Children's Research Hospital, Memphis, TN.

Department of Pediatrics, Clinical Education, University of Tennessee Health Science Center, Memphis, TN.

出版信息

Haematologica. 2022 Oct 1;107(10):2517-2522. doi: 10.3324/haematol.2022.280603.

DOI:10.3324/haematol.2022.280603
PMID:35615927
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9521228/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1e2/9521228/ec6ea1f87f12/1072517.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1e2/9521228/8c5de2da8cfe/1072517.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1e2/9521228/ec6ea1f87f12/1072517.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1e2/9521228/8c5de2da8cfe/1072517.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1e2/9521228/ec6ea1f87f12/1072517.fig2.jpg

相似文献

1
The successful use of eculizumab for treatment of thrombotic microangiopathy in pediatric acute SARSCoV2 infection and multisystem inflammatory syndrome in children.依库珠单抗成功用于治疗儿童急性SARS-CoV-2感染中的血栓性微血管病及儿童多系统炎症综合征。
Haematologica. 2022 Oct 1;107(10):2517-2522. doi: 10.3324/haematol.2022.280603.
2
Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.病例报告：成人新冠后多系统炎症综合征和血栓性微血管病。
Front Immunol. 2021 Jun 23;12:680567. doi: 10.3389/fimmu.2021.680567. eCollection 2021.
3
Thrombotic Microangiopathy Triggered by COVID-19: Case Reports.新冠病毒引发血栓性微血管病：病例报告。
Nephron. 2022;146(2):197-202. doi: 10.1159/000520144. Epub 2021 Nov 22.
4
The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.依库珠单抗在犬咬二氧化碳嗜纤维菌相关血栓性微血管病中的应用：一例报告
BMC Infect Dis. 2021 Feb 1;21(1):137. doi: 10.1186/s12879-021-05789-2.
5
Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.依库珠单抗用于治疗继发于手术侵袭性应激和出血的严重血栓性微血管病。
Intern Med. 2020;59(1):93-99. doi: 10.2169/internalmedicine.3315-19. Epub 2020 Jan 1.
6
Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.依库珠单抗治疗溃疡性结肠炎相关血栓性微血管病
Clin J Gastroenterol. 2020 Jun;13(3):344-348. doi: 10.1007/s12328-019-01052-z. Epub 2019 Oct 14.
7
A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab.1例心脏移植术后血栓性微血管病经依库珠单抗成功治疗。
Transpl Int. 2015 Jul;28(7):878-80. doi: 10.1111/tri.12551. Epub 2015 Mar 9.
8
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.依库珠单抗治疗儿童严重造血干细胞移植相关性血栓性微血管病。
Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25. doi: 10.1016/j.bbmt.2013.12.565. Epub 2013 Dec 25.
9
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.依库珠单抗在他克莫司诱导的血栓性微血管病中的应用。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620947266. doi: 10.1177/2324709620947266.
10
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.

引用本文的文献

1
Multisystem inflammatory syndrome in children and Kawasaki disease.儿童多系统炎症综合征与川崎病
Front Immunol. 2025 Apr 15;16:1554787. doi: 10.3389/fimmu.2025.1554787. eCollection 2025.
2
Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.儿童多系统炎症综合征的诊断与治疗进展
Front Immunol. 2025 Feb 19;16:1551122. doi: 10.3389/fimmu.2025.1551122. eCollection 2025.
3
Description of a national, multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry.

本文引用的文献

1
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）驱动JAK1/2依赖性局部补体过度激活。
Sci Immunol. 2021 Apr 7;6(58). doi: 10.1126/sciimmunol.abg0833.
2
Complement cascade in severe forms of COVID-19: Recent advances in therapy.补体级联反应在 COVID-19 严重形式中的作用：治疗的最新进展。
Eur J Immunol. 2021 Jul;51(7):1652-1659. doi: 10.1002/eji.202048959. Epub 2021 Apr 10.
3
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.
描述性研究：全国多中心镰状细胞病患者和 SARS-CoV-2 感染患者登记研究：来自儿科 COVID-19 美国登记处的数据。
Pediatr Blood Cancer. 2024 Jun;71(6):e30909. doi: 10.1002/pbc.30909. Epub 2024 Mar 12.
4
Sex-specific differences in systemic immune responses in MIS-C children.川崎病患儿全身免疫反应的性别特异性差异。
Sci Rep. 2024 Jan 19;14(1):1720. doi: 10.1038/s41598-024-52116-1.
5
The Rationale of Complement Blockade of the MCP Haplotype following Atypical Hemolytic Uremic Syndrome of Three Southeastern European Countries with a Literature Review.《三种东南欧国家非典型溶血尿毒症综合征后 MCP 单倍型补体阻断的理由：文献复习》
Int J Mol Sci. 2023 Aug 22;24(17):13041. doi: 10.3390/ijms241713041.
6
Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome.急性 COVID-19 或多系统炎症综合征患儿补体成分水平。
JAMA Netw Open. 2023 Mar 1;6(3):e231713. doi: 10.1001/jamanetworkopen.2023.1713.
7
Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?新生儿败血症和短暂性免疫缺陷：新型免疫球蛋白治疗的潜力？
Front Immunol. 2022 Oct 18;13:1016877. doi: 10.3389/fimmu.2022.1016877. eCollection 2022.
依库珠单抗作为重症监护病房中成年重症 COVID-19 患者的紧急治疗：一项概念验证研究。
EClinicalMedicine. 2020 Nov;28:100590. doi: 10.1016/j.eclinm.2020.100590. Epub 2020 Nov 5.
4
Complement activation and endothelial perturbation parallel COVID-19 severity and activity.补体激活和内皮功能紊乱与 COVID-19 的严重程度和活动并行。
J Autoimmun. 2021 Jan;116:102560. doi: 10.1016/j.jaut.2020.102560. Epub 2020 Oct 29.
5
Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.补体系统在 2019 年冠状病毒病病程中的作用及其对临床结局的影响。
J Infect Dis. 2021 Feb 3;223(2):214-224. doi: 10.1093/infdis/jiaa646.
6
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.SARS-CoV-2 刺突蛋白直接激活替代补体途径被因子 D 抑制所阻断。
Blood. 2020 Oct 29;136(18):2080-2089. doi: 10.1182/blood.2020008248.
7
Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.儿童多系统炎症综合征和 COVID-19 是 SARS-CoV-2 的不同表现形式。
J Clin Invest. 2020 Nov 2;130(11):5967-5975. doi: 10.1172/JCI140970.
8
Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.超越 HLH：噬血细胞性淋巴组织细胞增生症和血栓性微血管病同时表现患者的临床特征。
J Clin Immunol. 2020 Jul;40(5):699-707. doi: 10.1007/s10875-020-00789-4. Epub 2020 May 23.
9
Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.补体阻断治疗 TA-TMA：依库珠单抗治疗的大型儿科队列中获得的经验教训。
Blood. 2020 Mar 26;135(13):1049-1057. doi: 10.1182/blood.2019004218.
10
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.血管内溶血通过游离血红素和载血红素的微囊泡激活补体。
JCI Insight. 2018 Jun 21;3(12). doi: 10.1172/jci.insight.96910.